The recent article, “Inhibition of IL-11 Signalling Extends Mammalian Healthspan and Lifespan,” published in Nature on July 17th, constitutes a pivotal contribution to the realm of aging research and life extension strategies. This remarkable research, helmed by a consortium of distinguished scientists, has delved deep into the intricate interplay between pro-inflammatory cytokines, specifically interleukin-11 (IL-11), and the aging process in mammals. Let us embark on an in-depth analysis of this transformative study and its profound implications for the enhancement of healthspan and lifespan in mammalian models.
Unveiling the Role of IL-11 in Aging
The study has comprehensively unraveled the complex involvement of IL-11 in regulating crucial signaling cascades such as the ERK–AMPK–mTORC1 axis, which orchestrate age-associated diseases and lifespan. Through meticulous experimentation utilizing murine models, the research has illuminated the upregulation of IL-11 across diverse cell types and tissues during aging, thereby establishing its pivotal role in modulating cellular, tissue, and organismal-level aging pathologies.
Protective Effects of IL-11 Inhibition
A paramount revelation emerging from this research is the profound protective effects conferred by the deletion of Il11 or Il11ra1 against age-related metabolic decline, multi-morbidity, and frailty in old mice. Additionally, the administration of anti-IL-11 to aging mice has demonstrated substantial amelioration in metabolic function, muscle performance, and reduction in aging biomarkers and frailty, positioning IL-11 inhibition as a formidable strategy for mitigating age-related degeneration and frailty.
Lifespan Extension &Gender Disparities
Noteworthy findings from the study include the remarkable extension of the median lifespan in both male and female mice upon treatment with anti-IL-11. The magnitude of lifespan extension, amounting to over 20% in both sexes, underscores the profound impact and gender inclusivity of IL-11 inhibition as a longevity-promoting intervention. Furthermore, the study has shed light on the reduction in age-related cancers, thus underscoring the far-reaching implications of IL-11 inhibition in combating critical hallmarks of aging.
Insights into Chronic Inflammation, Immune Signaling & Aging
Furthermore, the research provides significant insights into the intricate interplay between chronic sterile inflammation, innate immune signaling, and the aging process. By elucidating the adverse impact of pro-inflammatory cytokines on age-related decline and lifespan extension in mammals, the study accentuates the indispensable role of inflammation in shaping age-related frailty, metabolic dysfunction, and multi-morbidity. Through in-depth investigations of invertebrates and mammalian models, the researchers have unveiled the multifaceted effects of IL-11 on senescence and aging phenotypes, shedding light on potential therapeutic avenues for addressing these critical age-related pathologies.
Translational Potential & Clinical Implications
Of particular significance is the translation of these research findings into potential therapeutic interventions for aging-associated conditions in humans. The viable prospects of employing anti-IL-11 therapy, currently under early-stage clinical trials for fibrotic lung disease, to unravel the effects of IL-11 inhibition on aging pathologies in older individuals hold immense promise for revolutionizing the landscape of aging research.
The transformative insights gleaned from this meticulous research delineate IL-11 as a central player in regulating mammalian healthspan and lifespan. The potential translational avenues for targeting IL-11 signify a paradigm shift in aging research and offer a beacon of hope for developing innovative interventions to enhance healthspan and lifespan in humans. This exemplifies a pivotal stepping stone towards the development of novel therapies with the potential to reshape the aging trajectory and foster a healthier, longer life for individuals across the lifespan.
In summary, the outstanding research outcomes and translational potential of IL-11 inhibition in extending healthspan and lifespan underscore the need for continued exploration and clinical validation of these promising interventions, with an overarching aim of ushering in a new era of age-optimizing therapeutics and strategies.
Here is the summary of the Research:
Impact of IL-11 on Age-Associated Disease and Lifespan:
– IL-11, a pro-inflammatory cytokine, plays a role in regulating ERK–AMPK–mTORC1 axis to modulate ageing pathologies.
– Deletion of Il11 or Il11ra1 in mice protects against metabolic decline, multi-morbidity, and frailty in old age.
Enhancing Metabolism and Reducing Frailty:
– Administering anti-IL-11 to 75-week-old mice improves metabolism, muscle function, and reduces ageing biomarkers and frailty.
– Genetic deletion of Il11 extends lifespan of mice of both sexes by an average of 24.9%.
Lifespan Extension Through Anti-IL-11 Therapy:
– Treatment with anti-IL-11 increases the median lifespan of male mice by 22.5% and of female mice by 25%.
– These results indicate a significant role for IL-11 in mammalian healthspan and lifespan.
Signalling Mechanisms Regulating Lifespan:
– Critical pathways including ERK, AMPK, mTORC1, and IGF1–insulin modules perturb in old age to activate hallmarks of ageing like mitochondrial dysfunction and inflammation.
– AMPK–mTORC1 axis is crucial for metabolic health in ageing organisms.
Ageing Studies and Interventions:
– Studies on ageing should focus on both lifespan and healthspan, rather than just extending lifespan.
– Laboratory mice are valuable in studying ageing pathologies and lifespan effects.
Role of Chronic Sterile Inflammation in Age-Associated Pathologies:
– Inflammation is central in ageing pathologies with dysfunctional immune system and activation of innate immune genes like IL-6.
– Pro-inflammatory factors like JAK–STAT3 are implicated in age-related dysfunction.
Upregulation of IL-11 with Age:
– IL-11 expression increases with age in liver, white adipose tissue, and skeletal muscle.
– Activation of IL-11 signalling module in liver and muscle is observed with ageing.
Cell Types Expressing Il11 in Old Mice:
– Progressive up-regulation of IL-11 is seen in various tissues of ageing mice.
– Querying Tabula Muris Senis confirms Il11 expression in aging cell types.
Diverse Expression of IL-11 with Age:
– IL-11 expression observed in various cell types in different tissues with ageing.
– Parenchymal and stromal cells across tissues showed IL-11 presence.
Association of IL-11 with Senescence:
– Old wild-type mice exhibited markers of senescence and cellular activation.
– Deletion of Il11ra1 led to improved metabolism and reduced senescence markers.
Metabolic Improvements with IL11RA1 Deletion:
– Il11ra1−/− mice had lower body weights and improved body composition.
– Ongoing maintenance of telomere lengths and mitochondria DNA in tissues.
Induction of Senescence by IL-11 in Human Cells:
– IL-11 activation led to increased senescence markers in human fibroblasts and hepatocytes.
– Effects were modulated by U0126 or rapamycin, impacting secretory phenotype factors.
Phenotypic Changes in Female Il11ra1-Deleted Mice:
– Old female Il11ra1−/− mice exhibited improvements in frailty, body composition, and metabolic health.
– Enhanced muscle strength and reduced frailty score observed in Il11−/− mice.
Protection from Age-Associated Effects in Il11-Deleted Female Mice:
– Il11−/− female mice showed lower body weights, fat mass, and improved lean mass with age.
– Overall protection from age-related obesity, frailty, and metabolic decline.
Key Metabolic and Physiological Changes in Il11-Deleted Female Mice:
– Improvements in muscle strength, serum cholesterol, triglycerides, and body temperature in aged Il11−/− mice.
– Decreased indexed vWAT weight, altered gene expression in vWAT, and changes in metabolic signaling pathways.
Preservation of Telomere Lengths and mtDNA in Il11−/− Mice:
– Significant preservation of telomere lengths and mtDNA copy numbers in tissues of old Il11−/− mice.
– Basal metabolic respiration impairment observed in control mice but not in Il11−/− mice.
Effects of IL-11 Inhibition on Liver Function and Metabolism in Old Mice:
– Old Il11−/− mice showed mitigated increases in serum AST, ALT, cholesterol, and triglycerides compared to old wild-type mice.
– Glucose tolerance and insulin resistance in old Il11−/− mice were similar to young wild-type mice.
Muscle and Adipose Tissue Changes in Il11−/− Mice:
– Both young and old Il11−/− mice had greater skeletal muscle mass compared to wild-type mice.
– Old Il11−/− mice had reduced liver and white adipose tissue mass compared to old wild-type mice.
Profile of Fatty Acid Synthesis Genes and Inflammatory Markers:
– Expression of fatty acid synthesis genes increased with age in old wild-type mice but not in old Il11−/− mice.
– Old wild-type mice showed increased pro-inflammatory gene expression in white adipose tissue compared to old Il11−/− mice.
Role of IL-11 Deletion in Mitigating ERK-MTORC1 Axis Activation and Senescence Markers:
– Activation of the ERK–mTORC1 axis and senescence markers were mitigated in white adipose tissue of old Il11−/− mice.
– Senescence markers and inflammatory gene expression were decreased in vWAT of old Il11−/− mice.
Improved Healthspan and Metabolic Flexibility in Old Male Il11−/− Mice:
– Old male Il11−/− mice exhibited less detrimental changes in body habitus, body weight, fat mass, lean mass, and frailty scores.
– They showed improved muscle strength and metabolic flexibility compared to old wild-type controls.
Therapeutic Inhibition of IL-11 in Old Male Mice:
– Administration of a neutralizing IL-11 antibody (X203) in aged mice reduced age-associated metabolic dysfunction and sarcopenia.
– Mice treated with X203 showed improvements in body weight, muscle strength, body temperature, and liver health.
Beneficial Effects of IL-11 Loss of Function in Both Young and Aged Mice:
– Some beneficial effects of Il11 loss of function, such as increased muscle mass and strength, were observed even in young Il11-deleted mice.
– Inhibition of IL-11 showed potential for improving healthspan and metabolic parameters in aged mice.
Comparative Analysis of IL-11 Inhibition and Aging Phenotypes in Mice:
– Comparative analysis showed that old Il11−/− mice demonstrated metabolic improvements similar to young mice.
– Therapeutic IL-11 inhibition in aged mice resulted in beneficial effects on body weight, muscle mass, and metabolic profiles.
Metabolic Improvements:
– Mice receiving X203 showed improved glucose metabolism compared to IgG-treated mice.
– The Respiratory Exchange Ratio (RER) was higher in X203-treated mice, indicating a slower age-associated metabolic decline.
Physical Health Benefits:
– Mice on X203 did not exhibit frailty progression seen in untreated or IgG-treated mice.
– Muscle strength in 100-week-old mice receiving anti-IL-11 was higher than age-matched controls.
Therapy Effects on Tissue and Organ Health:
– X203 therapy lowered serum cholesterol, triglycerides, IL-6 levels, and reduced hepatic triglyceride content.
– Mice on X203 showed a reduction in liver mass and increased muscle mass compared to control groups.
Inverse Aging Phenotypes:
– X203-treated mice had reduced tissue fibrosis in vWAT, skeletal muscle, and liver compared to aged-matched controls.
– Mice on X203 had diminished senescence markers and improved ERK-mTOR activity.
Effects on Female Mice:
– Old female mice on X203 lost body weight and had lower fat mass compared to IgG-treated mice.
– X203 therapy led to better glucose tolerance tests and insulin tolerance tests in female mice.
Molecular Mechanisms and Gene Expression:
– Mice on anti-IL-11 treatment had significant gene set enrichment for oxidative phosphorylation and metabolism.
– Anti-IL-11 therapy reduced markers of inflammation and activation of the IL-11-mTORC1 axis in vWAT.
Thermogenic Beige Adipocytes:
– X203 treatment upregulated Ucp1, a gene crucial for developing thermogenic ‘beige’ adipocytes in white adipose tissue.
– Genes related to senescence were mitigated in vWAT by anti-IL-11 therapy.
Inhibition of Senescence:
– Anti-IL-11 therapy inhibited senescence markers in aged vWAT, muscles, and livers.
– A reduction in senescence markers was particularly pronounced in vWAT of anti-IL-11-treated mice.
Up-regulation of Beiging Programme in vWAT:
– Upon closer inspection, up-regulation of a larger beiging programme was found in the vWAT of mice receiving anti-IL-11.
– This was evidenced by the upregulation of multiple genes associated with mitochondrial function and triglyceride metabolism.
Effects of IL-11 Inhibition on Lifespan:
– Inhibition of IL-11 was observed to extend the lifespan of male and female mice significantly.
– Mice receiving anti-IL-11 exhibited significantly longer lifespans compared to controls, with a reduction in age-related cancers.
Metabolic Effects of IL-11 Inhibition:
– Inhibition of IL-11 in old mice phenocopied the metabolic effects seen in young mice with WAT-specific deletion of Raptor.
– The inhibition of IL-11 was found to prevent mTORC1 activation in fat, leading to prominent age-repressed WAT beiging.
Overall Anti-ageing Benefits:
– Inhibition of IL-11 improved deterministic features of ageing such as frailty and sarcopenia, indicating generic anti-ageing benefits at the organismal level.
– The study also suggested the primacy of metabolic benefits and the importance of tissue-localized IL-11 activity.
Sex-Specific Lifespan Analyses:
– Sex-specific analyses revealed significant lifespan extension in both female and male mice with IL-11 inhibition.
– The administration of anti-IL-11 increased median lifespan by more than 20% in both sexes.
Effects of IL-11 Inhibition on Age-Related Cancers:
– Gross autopsy data revealed fewer macroscopic tumours in mice with Il11 deletion or on anti-IL-11 therapy, indicating a reduction in age-related cancers.
– This observation supported the notion that inhibition of IL-11 significantly reduces age-related cancers.
Role of IL-11 in Ageing Pathways:
– IL-11 was proposed to modulate multiple ageing pathways such as ERK, AMPK, mTOR, and JAK–STAT3, reflecting its pleiotropic benefits with inhibition.
– The study highlighted the importance of IL-11 in ageing-related pathogenic factors and its potential implications in age-related diseases.
Associations of IL-11 with Senescence and Diseases:
– IL-11 was linked with senescence and diseases common in older people, supported by its associations with osteoarthritis and menopause.
– This indicated the broader implications of IL-11 in age-related health conditions and ageing processes.
Innate Immune Signaling and Metabolism:
– Studies in invertebrates have shown that innate immune signaling, like Jak-Stat signaling in fly adipose tissue, can negatively impact metabolism and lifespan.
– This suggests a potential link between immune function and aging-related processes in mammals.
Signaling Pathways and Aging:
– The roles of canonical (JAK-STAT3) and non-canonical (MEK-ERK) IL-11 signaling in aging phenotypes are yet to be fully understood.
– Inhibition of ERK or mTOR, or activation of AMPK, can extend lifespan in model organisms but may have varying effects on healthspan and inflammation.
Anti-IL-11 Therapy for Longevity:
– Anti-IL-11 therapy, currently in early-stage clinical trials for fibroinflammatory diseases, has potential for extending human healthspan and lifespan.
– Its safety profile makes it a promising candidate for translating research findings to human applications.
Drugs and Lifespan Extension:
– Trametinib, rapamycin, and metformin, which act through AMPK or mTOR pathways, are suggested to increase lifespan in model organisms.
– However, their use in humans may be limited by toxicities and variable effects on healthspan.
– NSH Digi Desk
** **
For Original Research Paper click
Inhibition of IL-11 signalling extends mammalian healthspan and lifespan
